Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Gregory Vidal

Gregory Vidal MD, PhD

Medical Oncologist, West Cancer Center; Assistant Professor, Department of Hematology/Oncology, the University of Tennessee Health Science Center; Consultant, Vector Oncology Biopharmaceutical Development and Commercial Outsourcing Service; President and Co-Founder, Teuke Ouhayo Charitable Organization

Recent Contributions to PracticeUpdate:

  1. Atezolizumab Plus T-DM1 for Previously Treated HER2+ Advanced Breast Cancer
  2. Pembrolizumab vs Single-Agent Chemotherapy for Metastatic Triple-Negative Breast Cancer

Most Read This Week

Recently Updated